Brief: Instil Bio Announces Prioritization Of Genetically Engineered CoStAR-TIL Program With ITIL-306 In Advanced Solid Tumors And Reduction In Workforce

Instil Bio

08/12/2022 13:13

Dec 8 (Reuters) - Instil Bio Inc  TIL.O :
    * INSTIL BIO ANNOUNCES PRIORITIZATION OF GENETICALLY
ENGINEERED
COSTAR-TIL PROGRAM WITH ITIL-306 IN ADVANCED SOLID TUMORS AND
REDUCTION IN WORKFORCE
    * INSTIL BIO INC - REDUCING U.S. HEADCOUNT BY APPROXIMATELY
60%
    * INSTIL BIO INC - DISCONTINUING UNMODIFIED TIL PROGRAMS,
INCLUDING DELTA-1 AND DELTA-2 TRIALS OF ITIL-168
    * INSTIL BIO - PRIORITIZING COSTAR-TIL PROGRAMS FOR CLINICAL
DEVELOPMENT, INCLUDING ITIL-306 IN PHASE 1 TRIAL FOR NSCLC,
OVARIAN,  RENAL CELL CARCINOMA
    * INSTIL BIO INC - EXPECTS TO REPORT DATA FROM DOSE
ESCALATION
COHORTS OF PHASE 1 ITIL-306 STUDY IN 2023

Source text for Eikon:  ID:nGNX4nYxFv 
Further company coverage:  TIL.O 
 ((Reuters.Briefs@thomsonreuters.com;))